Conditions:  Bone Sarcoma;  Dedifferentiated Chondrosarcoma;  Giant Cell Tumor of Bone;  Malignancy in Giant Cell Tumor of Bone;  Malignant Solid Neoplasm;  Ovarian Carcinosarcoma;  Platinum-Resistant Ovarian Carcinoma;  Poorly Differentiated Thyroid Gland Carcinoma;  Recurrent Osteosarcoma;  Recurrent Ovarian Carcinoma;  Refractory Osteosarcoma;  Soft Tissue Sarcoma;  Thyroid Gland Anaplastic Carcinoma;  Thyroid Gland Squamous Cell Carcinoma;  Undifferentiated High Grade Pleomorphic Sarcoma of Bone;  Triple Negative Breast Cancer
Interventions:  Biological: Aldesleukin;  Biological: Autologous Tumor Infiltrating Lymphocytes LN-145;  Biological: Autologous Tumor Infiltrating Lymphocytes LN-145-S1;  Drug: Cyclophosphamide;  Drug: Fludarabine;  Biological: Ipilimumab;  Biological: Nivolumab;  Other: Quality-of-Life Assessment;  Other: Questionnaire Administration
Sponsors:  M.D. Anderson Cancer Center;  Iovance Biotherapeutics, Inc.;  National Cancer Institute (NCI)
**RECRUITING NOW**
Interventions:  Biological: Aldesleukin;  Biological: Autologous Tumor Infiltrating Lymphocytes LN-145;  Biological: Autologous Tumor Infiltrating Lymphocytes LN-145-S1;  Drug: Cyclophosphamide;  Drug: Fludarabine;  Biological: Ipilimumab;  Biological: Nivolumab;  Other: Quality-of-Life Assessment;  Other: Questionnaire Administration
Sponsors:  M.D. Anderson Cancer Center;  Iovance Biotherapeutics, Inc.;  National Cancer Institute (NCI)
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
